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Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a rare but potentially life-threatening
complication, frequently associated with Epstein-Barr virus (EBV), which develops after solid organ or
stem cell transplantation. Immunosuppression received by transplant recipients has a significant impact
on the development of PTLD by suppressing the function of T cells. The preferential proliferation of
NKG2A-positive natural killer (NK) cells during primary symptomatic EBV infection known as infectious
mononucleosis (IM) and their reactivity toward EBV-infected B cells point to a role of NK cell in the
immune control of EBV. However, NK cell-mediated immune response to EBV in immunosuppressed
transplant recipients who develop PTLD remains unclear. In this study, we longitudinally analyzed the
phenotype and function of different NK cell subsets in a cohort of pediatric liver transplant patients who
develop PTLD and compared them to those of children with IM. We found persistently elevated plasma
EBV DNA levels in the PTLD patients indicating suboptimal anti-viral immune control. PTLD patients
had markedly decreased frequency of CD56dimNKG2A+Killer Immunoglobulin-like receptor (KIR)−
NK cells from the time of diagnosis through remission compared to those of IM patients. Whilst the
proliferation of CD56dimNKG2A+KIR− NK cells was diminished in PTLD patients, this NK cell subset
maintained its ability to potently degranulate against EBV-infected B cells. Compared to cytomegalovirus
(CMV)-seropositive and -negative IM patients, PTLD patients co-infected with CMV and EBV had
significantly higher levels of a CMV-associated CD56dimNKG2ChiCD57+NKG2A−KIR+ NK cell subset
accumulating at the expense of NKG2A+KIR− NK cells. Taken together, our data indicate that co-
infection of CMV and EBV diminishes the frequency of CD56dimNKG2A+KIR− NK cells and contributes
to suboptimal control of EBV in immunosuppressed children with PTLD.
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Post-transplant lymphoproliferative disorder (PTLD) is a rare but potentially
life-threatening complication, frequently associated with Epstein-Barr virus (EBV),
which develops after solid organ or stem cell transplantation. Immunosuppression
received by transplant recipients has a significant impact on the development of PTLD
by suppressing the function of T cells. The preferential proliferation of NKG2A-positive
natural killer (NK) cells during primary symptomatic EBV infection known as infectious
mononucleosis (IM) and their reactivity toward EBV-infected B cells point to a role of NK
cell in the immune control of EBV. However, NK cell-mediated immune response to EBV
in immunosuppressed transplant recipients who develop PTLD remains unclear. In this
study, we longitudinally analyzed the phenotype and function of different NK cell subsets
in a cohort of pediatric liver transplant patients who develop PTLD and compared them
to those of children with IM. We found persistently elevated plasma EBV DNA levels in
the PTLD patients indicating suboptimal anti-viral immune control. PTLD patients had
markedly decreased frequency of CD56dimNKG2A+Killer Immunoglobulin-like receptor
(KIR)− NK cells from the time of diagnosis through remission compared to those of IM
patients. Whilst the proliferation of CD56dimNKG2A+KIR− NK cells was diminished in
PTLD patients, this NK cell subset maintained its ability to potently degranulate against
EBV-infected B cells. Compared to cytomegalovirus (CMV)-seropositive and -negative IM
patients, PTLD patients co-infected with CMV and EBV had significantly higher levels of
a CMV-associated CD56dimNKG2ChiCD57+NKG2A−KIR+ NK cell subset accumulating
at the expense of NKG2A+KIR− NK cells. Taken together, our data indicate that
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co-infection of CMV and EBV diminishes the frequency of CD56dimNKG2A+KIR− NK
cells and contributes to suboptimal control of EBV in immunosuppressed children
with PTLD.
Keywords: EBV, post-transplant lymphoproliferative disorder, infectious mononucleosis, natural killer cells,
NKG2A, KIR, immunosuppression, cytomegalovirus
INTRODUCTION
Epstein-Barr Virus (EBV) is a herpesvirus that latently infects
more than 90% of the world’s population (1). It is renowned for its
potent B-cell transforming capability to drive numerous benign
and malignant lymphoproliferative disorders such as infectious
mononucleosis (IM), post-transplant lymphoproliferative
disorder (PTLD), and Burkitt lymphoma (2). Contact with
saliva is known to be the major mode of transmission of
EBV, whereas solid organ or stem cell transplantation and
rarely blood transfusion can be alternative routes to transmit
EBV. Primary infection of EBV is usually asymptomatic and
occurs in early childhood, yet, delayed infection can develop
into IM.
IM is a self-limiting disorder characterized by extensive
proliferation of polyclonal EBV-specific CD8+ T cells in response
to primary EBV infection (3–5). Extensive work has been
performed to report the suppressive effect of T cells on EBV-
infected cells and our group has previously shown that the
emergence of polyfunctional CD4+ and CD8+ T cells plays a role
in viral control during IM (6). Besides T cells, the antiviral role of
natural killer (NK) cells in EBV-specific immune control has also
received attention in recent decades. Individuals with selective
primary NK cell deficiency exhibit an increased susceptibility to
EBV, associated with fatal primary infection or the development
of EBV-associated cancers (7, 8). In addition, depletion of
NK cells upon EBV infection of mice harboring humanized
immune system components is associated with higher EBV DNA
levels and points to a non-redundant antiviral role of these
immune cells (4). Furthermore, the preferential proliferation and
accumulation of early-differentiated CD56dimNKG2A+KIR−
NK cells in immunocompetent children with acute IM indicate
that the NK cell compartment reacts specifically to EBV (5).
This is also highlighted by the fact that other viral infections
are associated with the accumulation of another NK cell
subset, such as the late-differentiated CD56dimNKG2ChiCD57+
NK cell subset upon human cytomegalovirus (CMV) infection
(9). Finally, the demonstration of efficient in vitro killing of
autologous EBV-infected lymphoblastoid cell lines (LCL) by
NKG2A+ NK cells (10) indicates a potential role of NK cells in
the immune control of EBV-associated B cell cancers. The study
of IM patients provides insight in the pathogenesis and immune
control in primary EBV infection.
Compared to IM, less is known about EBV-specific
immune control in PTLD. PTLD is a rare but life-threatening
complication frequently associated with EBV which develops
after solid organ or stem cell transplantation (11, 12). The
incidence of PTLD is around 1–20% of solid organ transplant
recipients and depends on the transplanted organ, the degree
of immunosuppression and the serological EBV donor-
recipient constellation. For instance, adults who underwent
liver transplantation have an incidence of PTLD of around
1–4.3% (13, 14). However, in pediatric liver transplant
recipients, the incidence of PTLD is 6% in the first year,
and reaches a 5-year cumulative incidence rate of 20% (Chiang
AKS, unpublished data). The immunosuppressive regimen
and the EBV seronegative constellation of the solid organ
transplant (SOT) recipient frequently encountered in pediatric
transplantation are independent risk factors for the development
of PTLD (15). The impact of immunosuppression on T cell
functions has been reported extensively. Vafadari et al. (16)
reported that tacrolimus suppressed the T cell activation
via the NF-KB pathway. In line with this finding, Jones
et al. (17) also reported that the frequencies of EBNA1- and
BZLF1-specific CD4+ interferon gamma (IFNγ)-producing T
cells were decreased in PTLD patients compared to healthy
individuals. Another study reported increased PD-1 expression
on CD8+ T cells in transplant recipients with EBV infection
suggesting T cell exhaustion (18), although PD-1+ CD8+ T cells
retained protective functions in humanized mice infected with
EBV (19).
NK cells work complementary to T cells in controlling
tumors and viral infections. Their adaptive immune features
exhibited during viral infection in experimental mice (20)
and proliferation in humans during IM provide evidence that
NK cells also play a role in controlling EBV infection (5).
NK cells in the peripheral blood are composed of two main
subsets, i.e., CD56brightCD16− NK cells and CD56dimCD16+
NK cells that differ in terms of phenotype and function (21).
NK cells express activating receptors such as NKp46, NKp30,
and NKG2D and inhibitory receptors such as NKG2A and
KIRs. The balance between activating and inhibitory signals
upon recognition of virus-infected cells determines the NK
cell response (21, 22). To date, some NK studies in PTLD
patients have characterized the phenotype of NK cells, for
example, Wiesmayr et al. (23) reported a reduction of NKp46
and NKG2D surface expression level in pediatric PTLD patients
compared to healthy children and pediatric SOT recipients
without PTLD. However, the contribution of distinct NK cell
subsets to the immune control of EBV and the longitudinal
development of NK cell subsets in PTLD patients remain
largely unknown.
In the present study, we longitudinally assessed the phenotype
and function of NK cell subsets in the peripheral blood
of immunosuppressed pediatric liver transplant patients
who developed PTLD and compared them with those of
immunocompetent pediatric patients who developed IM.
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TABLE 1 | Basic characteristics of 17 IM and 15 PTLD patients at diagnosis.
IM (n = 17) PTLD (n = 15)
Age at diagnosis (years) 3.57 ± 2.04 2.56 ± 1.16
Male 12 5
Presence of EBV VCA IgM 14 10
EBV VCA IgG titers 2192.9 ± 2299.1 26176 ± 41328.7
Presence of EBNA IgG by
ACIF
0 2
EBV DNA levels at diagnosis
(copies/mL plasma)
103536 ± 211995.9 855272.60 ± 1957002
Mean ± standard deviation was shown. VCA, viral capsid antigen; EBNA, Epstein-Barr
nuclear antigen; ACIF, anti-complement immunofluorescence.
MATERIALS AND METHODS
Subject Recruitment
Fifteen pediatric liver transplant recipients diagnosed with
PTLD under 18 years of age were recruited and followed
longitudinally. The primary disease was biliary atresia (n =
15). Long term immunosuppressive regimen of the PTLD
patients consisted mainly of the calcineurin inhibitor, tacrolimus.
All patients included in this study were diagnosed to have
PTLD based on either histological examination of biopsy
tissues (n = 14) or radiological examination using PET-
CT scan (n = 1; Supplementary Table 1). EBV serological
status prior to liver transplantation was obtained (n =
11). Quantification of EBV copies and serological screening
for EBV were performed to confirm the infection status
at diagnosis of PTLD (Table 1). PTLD patients who tested
positive or negative for EBV viral capsid antigen (VCA)
IgM and positive for VCA IgG but negative for Epstein-
Barr nuclear antigen (EBNA) IgG were considered to have
primary EBV infection. The majority of the patients had
primary EBV infection at diagnosis of PTLD (n = 13). All
PTLD patients showed EBV and CMV seroconversion. Detailed
clinical characteristics of the PTLD patients are listed in
Supplementary Table 1.
Seventeen pediatric acute IM patients were also recruited
and followed longitudinally. Patients with typical IM symptoms,
such as fever, sore throat and lymphadenopathy, who tested
positive or negative for EBV VCA IgM and positive for VCA
IgG but negative for EBNA IgG were enrolled in this study
(Table 1). Twenty healthy adults were recruited and served as
healthy controls.
Heparinized peripheral blood samples were collected at
the following time points, diagnosis, around 1 month, 3
months, 6 months, and 12 months. Additionally, the sample
collection of PTLD patients continued at yearly intervals
post-diagnosis. If sampling was performed at time points
varying from the above mentioned analysis time points, e.g.,
for clinical reasons, the sample closest to the missing time
point was selected. The mean time post-diagnosis and the
standard deviation between the proposed and the actual time
point selected are listed for all PTLD and IM subjects in
Supplementary Table 2.
Plasma was isolated from each individual and stored at
−80
◦
C until use. Peripheral blood mononuclear cells (PBMCs)
were isolated by standard Ficoll-Hypaque density gradient
centrifugation. Collected PBMCs were cryopreserved in fetal
bovine serum (FBS) (Invitrogen, CA) with 10% DMSO in liquid
nitrogen until use.
All patient samples were handled as potential biohazardous
materials following the institutional safety procedures. The study
protocols were approved by the Institutional Review Board of
The University of Hong Kong. Informed written consent was
obtained from each participant prior to the study in accordance
with the Declaration of Helsinki.
DNA Extraction and Quantification of EBV
Copies
The NucliSENS easyMag instrument (BioMerieux) was used to
extract DNA from plasma in accordance to the manufacturer’s
instruction. Plasma EBV DNA levels were determined by
detecting the EBV BamH1_W repeats in EBV genomes by
quantitative PCR (qPCR) with ABI PRISM 7900 sequence
detector (Applied Biosystems). The forward and reverse primers
with the following sequences were used: 5′-GGTCGCCCAG
TCCTACCA-3′ and 5′-GCTTACCACCTCCTCTTCTTGCT-3′,
respectively. The FAM-labeled probe consisted of the following
sequence: 5′-CCAAGAACCCAGACGAGTCCGTAGAAGG-3′.
Standard curve for copy numbers were obtained using serial
dilutions of Namalwa DNA. All samples were performed in
triplicate and the mean results were reported as EBV copies per
mL plasma.
Analysis of NK Cell Subset Phenotype and
Proliferation
Frozen PBMCs were thawed, washed and stained with the
following combination of monoclonal antibodies, Pacific Blue-
conjugated anti-CD3 (Biolegend), PE-Cy7-conjugated anti-
CD56 (BD pharmingen), APC-Cy7-conjugated anti-CD16, PE-
conjugated anti-NKG2A (Beckman Coulter), APC-conjugated
anti-CD158a/h (Biolegend), APC-conjugated anti-CD158b1/b2/j
(Biolegend), APC-conjugated anti-KIR3DL1 (Biolegend), Alexa
Fluor 488-conjugated anti-NKG2C (R&D Systems), APC-
Cy7-conjugated anti-CD27 (BD pharmingen), and PerCP-
Cy5.5 conjugated anti-CD57 (Biolegend) monoclonal antibody.
LIVE/DEAD Fixable Aqua was used for dead cell exclusion
in every phenotypic analysis. The stained cells were then
washed, fixed and permeabilized by BD Cytofix/Cytoperm
Fixation/Permeabilization kit (BD Biosciences) according to
the manufacturer’s protocol. Subsequently, cells were washed
and stained intracellularly with FITC-conjugated anti-Ki67 (BD
Pharmingen) for 30min at 4
◦
C. Cells were washed and re-
suspended in PBS prior to flow cytometric analysis. Cells were
acquired on FACS LSR-II and LSR Fortessa (BD Biosciences) and
FACS data was analyzed by FlowJo v10 (BD). Samples with<20%
live lymphocytes were excluded from the analysis.
Stimulation of NK Cells
Frozen PBMCs were thawed and rested overnight in 10%
FBS/RPMI 1640 with stimulation of IL-2 (100 U/mL). PBMCs
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(5 × 105) were subsequently co-cultured with LCL721.221 or
K562 at an effector-to-target ratio of 10:1 for 6 h at 37◦C, 5%
CO2 in the presence of Pacific Blue-conjugated anti-CD107a
(Biolegend). After 1 h of incubation, the protein transport
inhibitor Monensin (1µg/ml BD Golgi Stop, BD Pharmingen)
was added to all samples. PBMCs only and PBMCs stimulated
with PMA (5 ng/mL) and Ionomycin (500 ng/mL) were used as
negative and positive controls, respectively.
Flow Cytometry Based Degranulation
Assay
After incubation for 6 h, cells were stained with the following
combination of monoclonal antibodies, FITC-conjugated
anti-CD3 (Biolegend), PE-Cy7-conjugated anti-CD56 (BD
pharmingen), PE-conjugated anti-NKG2A (Beckman Coulter),
APC-conjugated anti-CD158a/h (Biolegend), APC-conjugated
anti-CD158b1/b2/j (Biolegend), and APC-conjugated anti-
KIR3DL1 (Biolegend) monoclonal antibody for surface
marker staining. LIVE/DEAD Fixable Aqua (Invitrogen) was
stained for dead cell exclusion in each sample. The stained
cells were subsequently washed, fixed, and permeabilized
by BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD
Biosciences) according to the manufacturer’s protocol. Cells
were washed and re-suspended in PBS prior to flow cytometric
analysis. Cells were acquired on FACS LSR-II flow cytometer (BD
Biosciences) and FACS data were analyzed by FlowJo v10 (BD).
Samples with <20% live lymphocytes were excluded from the
analysis. The spontaneous degranulation signals from PBMCs
only were subtracted in each analysis.
Cell Lines
LCL721.221 and K562 were maintained in 10% fetal bovine
serum (FBS)/RPMI 1640. Both cell lines tested negative for
mycoplasma contamination.
Statistical Analysis
Wilcoxon matched-pairs signed rank tests and Mann-Whitney
tests were applied to compare data derived from one group or
those between groups, respectively. Correlation between plasma
EBV DNA levels and blood tacrolimus levels in pediatric PTLD
patients was determined by Spearman test. A p < 0.05 was
regarded as statistically significant. Prism 6 (GraphPad Software,
La Jolla, CA) was used for calculations and illustrations.
RESULTS
PTLD Patients Exhibit Persistently
Elevated Plasma EBV DNA Levels Up to 24
Months After Diagnosis
EBV DNA levels in the plasma of 17 pediatric IM patients
and 15 pediatric liver transplant patients with PTLD were
quantified longitudinally via qPCR starting at the time point
of diagnosis until 12 and 24 months later, respectively. In
addition, we assessed plasma EBV DNA levels of 20 healthy
adults, amongst whom only one had plasma viremia above the
detection threshold. In contrast, we found elevated EBV DNA
levels in the plasma of both IM and PTLD patients at diagnosis,
yet levels in PTLD patients were significantly higher (Figure 1A).
The median plasma EBV DNA levels decreased in both cohorts
starting 1 month after diagnosis. Although EBV DNA levels were
below the detection limit in most of the IM patients at 3 months
after diagnosis, EBV DNA levels remained elevated in more
than half of the PTLD patients during the follow-up and only
decreased slowly over time. At 12 months post-diagnosis, plasma
EBV viremia was found in 82% of PTLD patients (9 out of 11)
compared to 7% of IM patients (1 out of 15). Even 2 years post-
diagnosis, 50% of PTLD patients had detectable EBV DNA levels
in the plasma (Supplementary Figure 1). These results suggest
that EBV DNA levels tend to persist at elevated levels in PTLD
patients after clinical recovery.
Plasma EBV DNA and Blood Tacrolimus
Levels Correlate Weakly in PTLD Patients
Previous studies reported that a subgroup of immunosuppressed
solid organ transplant recipients exhibited subclinical high
EBV DNA levels after transplantation without developing EBV-
associated PTLD (24, 25). In some of these patients, EBV
viremia persisted for several months and a link with the
immunosuppressive treatment was postulated. Therefore, we
assessed the kinetic changes of plasma EBV DNA and trough
blood tacrolimus levels in 15 PTLD patients individually from the
time of diagnosis through longitudinal time points.
We found that patients with increased blood tacrolimus levels
had increased plasma EBV DNA levels (Figure 1B). In general,
most of the patients had lower tacrolimus levels and exhibited
decrease in plasma EBVDNA levels during recovery, likely owing
to the reductions in immunosuppressive treatment following
diagnosis of PTLD. Nevertheless, a weak positive correlation
between blood tacrolimus and plasma EBVDNA levels was found
in PTLD patients (r = 0.1620; p= 0.0191; Figure 1C).
In line with previously published results on the effect of
immunosuppression and EBVDNA levels on the development of
PTLD (26, 27), these findings suggest that immunosuppression
leads to suboptimal immune control of EBV as indicated
by the persistently elevated plasma EBV DNA levels in the
PTLD patients.
The Frequency of CD56dimNKG2A+KIR−
NK Cells Is Significantly Higher in IM Than
in PTLD Patients
Immunosuppressive drugs administered to transplant recipients,
such as tacrolimus, inhibit the function of T cells that could cause
graft rejection, but increase the risk for PTLD (1, 2). Besides T
cells, several studies have reported potential roles of NK cells in
EBV control (4, 5). To identify NK cell subsets that could play a
role in the immune control of EBV, we assessed the frequencies
of different NK cell subsets in 17 IM and 15 PTLD patients at
time points ranging from diagnosis (D0) to 12 or 24 months,
respectively, via flow cytometric analysis (Figures 2A,B).
Overall frequencies of CD3−CD56+ NK cells did not differ
between both cohorts of patients at different time points
(Supplementary Figure 2A). In both cohorts, the CD56dim NK
cell subset represented more than 90% of the NK cells in
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FIGURE 1 | PTLD patients exhibit persistently elevated plasma EBV DNA levels up to 12 months after diagnosis and plasma EBV DNA levels show weak correlation
with blood tacrolimus levels. (A) Plasma EBV DNA levels in IM patients and PTLD patients were assessed at diagnosis, as well as during recovery at 1, 3, 6, and 12
months post-diagnosis. Twenty healthy adults were used as healthy controls for detecting baseline EBV DNA levels. (B) Kinetics of plasma EBV DNA levels and blood
tacrolimus levels in 1 representative PTLD patient is plotted from diagnosis (D0) to longitudinal time points. Blood tacrolimus levels ≤2 µg/L were not detectable and
are plotted on the dotted line depicting the detection limit. The date of PTLD diagnosis, the period and treatment of each PTLD patient (gray area) are also plotted. The
plasma EBV DNA levels (red line) are plotted on left y-axis, while the blood tacrolimus levels (blue line) are plotted on right y-axis. (C) Relationship between plasma
EBV DNA levels and the blood tacrolimus levels in 13 PTLD patients at various time points ranging from diagnosis to their latest follow-up time points. Two patients
were excluded due to the lack of measurable pairs of tacrolimus levels and plasma EBV DNA levels for the analysis. EBV DNA levels were quantified by qPCR and
reported as EBV copy numbers per ml plasma. Median ± interquartile range is shown. Mann-Whitney tests were applied to compare the plasma EBV DNA levels in
different cohorts of patients at all time points. Two-tailed spearman test was applied to calculate the correlation between plasma EBV DNA levels and blood tacrolimus
in PTLD patients. U, undetectable level; dotted line, limit of detection of tacrolimus in blood; ns, p > 0.05; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; and ****p ≤ 0.0001.
peripheral blood as previously reported in healthy individuals
(Supplementary Figure 2B). The median frequency of the
CD56bright NK cell subset also did not differ between IM and
PTLD patients (data not shown). Interestingly, a significant
decrease in the frequency of CD56dim NK cell subset was
observed in IM patients after 3 and 6 months, while in PTLD
patients, it remained stable throughout the observation period.
Next, we assessed the distribution of subsets within CD56dim
NK cells according to the expression of the inhibitory
receptors, NKG2A and KIRs. Strikingly, the majority of CD56dim
NK cells in IM patients was NKG2A+KIR− (Figure 2C),
while in PTLD patients, the majority was NKG2A−KIR+
(Figure 2D). Similar to PTLD patients, healthy controls showed
a majority of NKG2A−KIR+ NK cell subset within CD56dim
NK cells (data not shown). Analysis of the subset frequencies
within the first year post-diagnosis demonstrated significant
differences between the two patient cohorts. The frequencies of
CD56dimNKG2A+KIR− NK cells over time were significantly
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FIGURE 2 | The frequency of CD56dim NKG2A+KIR− NK cells is significantly higher in IM than in PTLD patients. (A) Gating strategy for flow cytometric analysis of
CD56+ NK cells in 1 representative PTLD patient at diagnosis. (B) Gating strategy for flow cytometric analysis of CD56dimNKG2A−KIR+ and CD56dimNKG2A−KIR+
NK cell subsets in representative IM and PTLD patients. (C, D) The mean ± SD showing (C) CD56dimNKG2A+KIR− NK cell frequency over time and (D)
CD56dimNKG2A−KIR+ NK cell frequency over time in 15 IM and 13 PTLD patients from diagnosis to 12 months post-diagnosis time point. (E) Median ± interquartile
range and minimum and maximum values of area-under-the-curve (AUC) of CD56dimNKG2A+KIR− NK cell frequency vs. time (from C) and (F) CD56dimNKG2A−KIR+
NK cell frequency vs. time (from D) between IM and PTLD patients compared via Mann-Whitney tests. ***p ≤ 0.001. Blue line, IM patients; Pink line, PTLD patients.
higher in IM patients (Figure 2E), whereas in PTLD patients,
NKG2A−KIR+ subset frequencies over time were significantly
higher (Figure 2F). We then examined whether treatment
administered to PTLD patients affected the frequencies of
NKG2A+KIR− and NKG2A−KIR+ NK cells. No significant
difference was shown in the frequencies of NKG2A+KIR− and
NKG2A−KIR+ NK cells before and after treatment of PTLD
patients (Supplementary Figures 2C,D). Thus, the observed
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FIGURE 3 | CD56dimNKG2A+KIR− NK cells proliferate less in PTLD compared to those in IM patients shortly after diagnosis. (A) Flow cytometric gating of the
frequency of Ki-67 expressing cells of CD56dimNKG2A+KIR− and CD56dimNKG2A−KIR+ NK cell subsets with isotype control antibody or anti-human Ki67 antibody in
1 representative IM patient. Frequency change of Ki-67 expressing cells of (B) CD56dimNKG2A+KIR− NK cell subset and (C) CD56dimNKG2A−KIR+ NK cell subsets
in 17 IM and 15 PTLD patients at diagnosis and 1 month post-diagnosis, respectively. Median ± interquartile range is shown. Mann-Whitney tests were applied to
compare different groups. ns, p > 0.05 and *p ≤ 0.05.
quantitative deficiency of protective CD56dimNKG2A+KIR− NK
cells might contribute to suboptimal immune control of EBV
associated with the development of PTLD.
CD56dimNKG2A+KIR− NK Cells Proliferate
Less in PTLD Than in IM Patients
We next investigated whether differences in NK cell proliferation
could explain the lower frequencies of CD56dimNKG2A+KIR−
NK cells in PTLD patients. To that end, we assessed the
expression of the intranuclear proliferation marker Ki-67 within
the different NK cell subsets (Figure 3). The frequency of Ki-67+
cells within the CD56dimNKG2A+KIR− subset was significantly
higher in IM than in PTLD patients during the acute phase of
the disease (Figure 3B). Moreover, unlike in IM subjects, only a
low frequency of NKG2A+KIR− NK cells proliferated in PTLD
patients during the observation period. In contrast, the levels
of Ki-67 expressing cells among CD56dimNKG2A−KIR+ cells
did not significantly differ between the two patient cohorts nor
did they change over time (Figure 3C). Minimal proliferation
of CD56dimNKG2A+KIR− NK cells was detected in the healthy
controls (data not shown).
The increased proliferation in CD56dimNKG2A+KIR− NK
cells compared to the CD56dimNKG2A−KIR+ NK cells in
acute IM patients is in line with one previous study (5) and
supports previous evidence for an important role of this subset in
resolving this self-limiting disease. Furthermore, it suggests that
a deficiency in this subset may contribute to the suboptimal viral
immune control observed in PTLD.
Degranulation of CD56dimNKG2A+KIR− NK
Cell Subset in Response to EBV-Infected B
Cells Is Maintained in PTLD Patients
We performed degranulation assays to examine differences
in the protective effects of NK cell subsets obtained from the
two patient cohorts after clinical recovery. Upon contact with
the HLA class I negative EBV-infected B cell line LCL721.221,
the CD56dimNKG2A+KIR− NK cell subset degranulated
significantly more than the CD56dimNKG2A−KIR+ subset
in both patient cohorts, as determined by CD107a staining
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FIGURE 4 | CD56dimNKG2A+KIR− NK cells of both PTLD and IM patients
exhibited comparable cytotoxic degranulation in response to EBV-infected B
cells. PBMCs from 16 IM patients at the 12 months recovery time point and
PBMCs from 13 PTLD patients at the 24 months recovery time point were
stimulated with IL-2 overnight prior to co-culture with the HLA class I negative
EBV-infected B cell line LCL721.221 on the next day at effector to target ratio
of 10:1 for 6 h. Frequencies of cells with CD107a surface expression in the
CD56dimNKG2A+KIR− and CD56dimNKG2A−KIR+ NK cell subsets in 16 IM
patients and 13 PTLD patients were assessed by flow cytometry at the end of
the co-culture. Every line represents 1 individual. Wilcoxon matched-pairs
signed rank tests were applied to compare data from one group. **p ≤ 0.01.
(Figure 4). The same effect was observed against the HLA-I
and II negative erythroleukemia cell line K562, which generally
elicited a stronger response (Supplementary Figure 3). The
similar cytotoxicity of CD56dimNKG2A+KIR− NK cells from
IM and PTLD patients argues against different NKG2Amediated
licensing due to different HLA class I distribution in the two
patient cohorts (28).
In addition, the degranulation potency of
CD56dimNKG2A+KIR− NK cell subsets in response to
LCL721.221 (Figure 4) or K562 (Supplementary Figure 3)
was not different between the two patient cohorts. The similar
cytotoxicity of CD56dimNKG2A−KIR+ NK cells from IM
and PTLD patients argues against different KIR mediated
licensing due to different HLA class I distribution in the
two patient cohorts (29). These findings suggest that the
CD56dimNKG2A+KIR− NK cell subset in PTLD patients is
capable of efficient degranulation upon challenge by latently
EBV-infected B cells and contributes to targeting EBV-infected
B cells. The suboptimal EBV-specific immune control at
later time points after diagnosis in PTLD patients correlates
with the diminished frequency of potent degranulating
CD56dimNKG2A+KIR− NK cells compared to that of
IM patients.
Expansion of CD56dimNKG2ChiCD57+ NK
Cells Is Associated With Diminished
Frequency of CD56dimNKG2A+KIR− NK
Cells in PTLD Patients
CMV infection is known to drive the accumulation of late-
differentiated CD56dimNKG2ChiCD57+ NK cells (9). Expression
of the receptors NKG2A and NKG2C requires covalent assembly
with CD94 as a heterodimer (30) and is usually mutually
exclusive on NK cells. Both NKG2A and NKG2C bind to
the non-classical HLA-class I HLA-E (31) and deliver upon
binding an inhibitory and activating signal, respectively. Since
all PTLD patients in our cohort were CMV-seropositive,
we set out to examine whether CMV skews the NK cell
repertoire toward late-differentiated cells at the expense of
CD56dimNKG2A+KIR− NK cells. To that end, we assessed the
frequency of CD56dimNKG2ChiCD57+ NK cells in 7 CMV-
seronegative IM, 6 CMV-seropositive IM and 11 PTLD patients
(Figure 5A). In agreement with previous findings (9), higher
frequency of CD56dimNKG2ChiCD57+ NK cells was found
in CMV-seropositive IM patients compared to that of CMV-
seronegative IM patients, and interestingly, PTLD patients
showed the highest frequency of CD56dimNKG2ChiCD57+ NK
cells (Figure 5B). No significant change in the subset frequency
over time was found in either of the CMV-seropositive patient
cohorts (Figure 5B).
Subsequently, we assessed the expression of NKG2A and
KIR in CD56dimNKG2ChiCD57+ NK cells of CMV-seropositive
patients. The vast majority of CD56dimNKG2ChiCD57+ NK cells
was NKG2A−KIR+ (Figures 5C,D).
CD56dimNKG2A+KIR−CD57+ NK Cells Are
More Frequently Found in IM Than in PTLD
Patients at 12 Months Post-diagnosis
The acquisition of the terminally differentiation marker, CD57,
on CD56dim NKG2C+ NK cells upon CMV infection (9) and
on CD56dimNKG2A+KIR− NK cells upon EBV infection
(5) has been hypothetically linked to the development of
NK cell memory. Therefore, we assessed the maturation
status of CD56dimNKG2A+KIR− and NKG2A−KIR+
NK cell subsets using CD57 and the early-differentiation
marker CD27 as control. Low but increased frequencies of
CD27+ cells were found within CD56dimNKG2A+KIR− and
CD56dimNKG2A−KIR+ NK cell subsets in IM patients over
time. Increased frequencies of CD27+ cells were only found
within CD56dimNKG2A+KIR− NK cell subset in PTLD patients
over time. The frequency of CD27+CD56dimNKG2A−KIR+
NK cells was significantly lower in PTLD than IM patients at 12
months post-diagnosis (Supplementary Figure 4).
Furthermore, only few CD56dimNKG2A+KIR− NK cells were
CD57+ at the time point of diagnosis of IM and PTLD, yet,
the frequency of CD57+CD56dimNKG2A+KIR− NK cells was
significantly increased in IM patients at 12months post-diagnosis
(Figure 5E). This might suggest the emergence of memory-like
CD56dimNKG2A+KIR−CD57+NK cells during IM and their
persistence upon remission of the disease. In contrast, the
frequency of memory-like NK cells remained low in PTLD
patients, consistent with the suboptimal control of EBV.
DISCUSSION
EBV is associated with the development of PTLD in
immunosuppressed individuals such as transplant recipients.
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FIGURE 5 | CD56dimNKG2ChiCD57+ NK cells are found in higher frequency in PTLD than in IM patients. (A) Gating strategy for flow cytometric analysis of
CD56dimNKG2ChiCD57+ cells in representative CMV-seronegative (CMV–) IM, CMV-seropositive (CMV+) IM and PTLD patients at diagnosis. (B) Frequency of
CD56dimNKG2ChiCD57+ NK cells in 7 CMV– IM, 6 CMV+ IM and 11 PTLD patients at diagnosis and 12 months time points. (C) Frequency of NKG2A+KIR− and (D)
NKG2A−KIR+ within CD56dimNKG2ChiCD57+ NK cells in CMV-seropositive IM and PTLD patients at diagnosis. Three CMV-seropositive IM patients were excluded in
the sub-gating analysis of CD56dimNKG2ChiCD57+ NK cell subset due to the nearly absence of CD56dimNKG2ChiCD57+ NK cells. Every dot or triangle represents
individual IM and PTLD patients, respectively. CMV-seropositive IM patients are highlighted as red circles. All PTLD patients were seropositive for CMV after liver
transplantation. (E) Frequency of CD57+ cells within CD56dim NKG2A+KIR− NK cell subset was assessed in 13 IM and 11 PTLD patients at diagnosis to 12 months
time points. Median ± interquartile range is shown. Mann-Whitney tests were applied to compare frequencies of NK cell subsets from one group or for comparisons
between groups in IM and PTLD patients over time. ns, p > 0.05; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; and ****p ≤ 0.0001.
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The majority of pediatric PTLD are attributable to primary EBV
infection (11). With regard to the high-risk of developing PTLD
in pediatric transplant recipients, routine monitoring of EBV
DNA levels is recommended (32). EBV copy quantification has
been used as standard practice to assess the immune control of
EBV infection and determine the risk for PTLD of transplant
recipients during immunosuppressive therapy. Although
measurement of EBV copies in peripheral blood mononuclear
cells (PBMCs) has been reported to reflect the EBV-infected
circulating B cell population (27), plasma EBV viral copies have
been found to be better in predicting the clinical outcomes for
the management of PTLD (33). In this study, plasma EBV DNA
levels were longitudinally followed as references of viral immune
control in both pediatric IM and PTLD patients. Plasma EBV
DNA levels were also determined in healthy donors, which
served as controls.
We observed elevated plasma EBV DNA levels at the time of
diagnosis in PTLD patients, which remained elevated during the
longitudinal time points despite clinical remission. In contrast,
plasma EBV DNA levels of IM patients dropped briskly after 1
month post-diagnosis and levels after remission were similar to
those of healthy controls. However, EBV DNA levels were not
predictive of the clinical outcome and persisted at high levels
in pediatric liver transplant recipients irrespective of clinical
recovery from PTLD. This is consistent with previous reports,
as high plasma EBV DNA levels were also found in pediatric
liver transplant recipients and liver transplant recipients who
had recovered from PTLD, in the absence of clinical symptoms
or recurrence of PTLD (25, 34, 35). This suggests that high
EBV DNA levels are not necessarily predictive of clinical disease.
However, we identified a weak correlation between plasma EBV
and blood tacrolimus levels in our cohort of PTLD patients.
In line with this observation, Guthery et al. (26) reported that
immunosuppression with tacrolimus at transplantation was an
independent risk factor for development of PTLD in pediatric
liver transplant recipients. Thus, chronically elevated plasma
EBVDNA levels after recovery fromPTLDmay be an indicator of
suboptimal viral immune control caused by immunosuppression
with tacrolimus.
Immunosuppression in transplant recipients has been
recognized as a contributing factor to the suboptimal viral
immune control and development of PTLD (1, 2). T cells, as
the major effectors in immune control of EBV (36–38), have
thus been extensively studied for their functions under the
effect of immunosuppression. Suppressed T cell activation
and diminished frequency of EBV-specific CD4+ T cells have
been reported in PTLD patients compared to those of control
transplant recipients (16, 17). These studies indicated that PTLD
patients have an impairment of EBV-specific T cells. Previous
studies have documented the complementary roles played by NK
cells in viral immune control (4, 5, 10). We postulate that NK
cells might also be impaired in the immunosuppressed PTLD
patients contributing to the emergence of PTLD.
No significant differences in the frequency of CD56+
and CD56dim NK cells were identified between the cohorts
of IM and PTLD throughout the observation period.
CD56dimNKG2A+KIR− NK cells have been described to
target both latent and lytic EBV infection in vitro (5, 10).
In line with the previously published results, we found
a selective accumulation of CD56dimNKG2A+KIR− NK
cells in IM patients. In contrast, a diminished frequency of
CD56dimNKG2A+KIR− NK cells was observed at diagnosis in
PTLD patients that even persisted for years after recovery. As
a result, late-differentiated CD56dimNKG2A−KIR+ NK cells
formed the predominant subset in PTLD patients at all time
points measured. No significant impact on the frequency of
CD56dimNKG2A+KIR− NK cells by the treatment of PTLD
was identified. Yet, CD56dimNKG2A+KIR− NK cells of PTLD
patients proliferated significantly less at diagnosis and 1 month
compared to those of IM patients, despite the presence of higher
plasma EBV DNA levels in the former.
This difference in the frequency of NK cell subsets and the
associated changes in overall NK cell function could contribute to
the suboptimal EBV-specific immune control in PTLD patients.
Yet, CD56dimNKG2A+KIR− NK cells of PTLD and IM patients
exhibited comparable cytotoxic response ex vivo. Therefore,
we did not find any quantitative impairment in the NK cell
mediated cytotoxicity in PTLD patients despite the presence of
tacrolimus-mediated immunosuppression. The low frequency of
CD56dimNKG2A+KIR− NK cells compared to that of the IM
patients could explain in part the suboptimal control of EBV
viremia in PTLD patients.
Co-infection of CMV and EBV is common in
immunosuppressed pediatric transplant recipients and all
PTLD patients in our cohort were CMV-seropositive after
transplantation. The CMV serology conversions in these patients
might be caused by the CMV-positive graft they received or
were already present before transplantation. According to
Achour et al. (39) accumulation of CD56dimNKG2ChiCD57+
NK cells was found in CMV-seropositive orthotopic liver
transplant recipients and the percentage of NKG2C+
NK cells was found to be inversely correlated with that
of NKG2A+ NK cells. We investigated whether CMV
co-infection could explain the diminished number of
CD56dimNKG2A+KIR− NK cells by possibly differentiating
them into CD56dimNKG2C+ (NKG2A−) KIR+ NK cells in
PTLD patients.
Since no CMV-seronegative liver transplant recipient
was recruited in this study, we compared the frequencies of
CD56dimNKG2ChiCD57+ NK cells in the PTLD patients to
those of CMV-seronegative and -seropositive IM patients.
Robust levels of the CD56dimNKG2ChiCD57+ NK cell subset
were only found in CMV-seropositive individuals, whereby the
accumulation of this subset was significantly greater in PTLD
compared to CMV-seropositive IM patients (Figure 5B). In line
with a mature NK cell phenotype, CD56dimNKG2ChiCD57+ NK
cells were NKG2A−KIR+ (Figure 5D). Such CMV-associated
CD56dimNKG2ChiCD57+ NK cells might be maintained by
subclinical CMV reactivation after acute CMV infection (9).
Immunosuppressed PTLD patients have repeated episodes
of CMV reactivation, which might lead to more frequent
differentiation of CD56dimNKG2A+KIR− NK cells into
CD56dimNKG2ChiCD57+NKG2A−KIR+ NK cells and their
long-term persistence.
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On the other hand, the expression of the terminal
differentiation marker CD57 on CD56dimNKG2Chi NK
cells has been proposed to indicate memory-like properties
after acute CMV infection (9, 40). The significant increase in
the frequency of CD57+CD56dimNKG2A+KIR− NK cells in
IM patients at 12 months post-diagnosis could indicate the
presence of memory-like CD56dimNKG2A+KIR− NK cells,
which may contribute to the long-term control of EBV. Together,
the data suggest that CMV infection in immunosuppressed
PTLD patients drives NK cells to terminally differentiated
NKG2ChiCD57+NKG2A−KIR+ NK cell subset as described in
other settings and might impair the generation and maintenance
of EBV-reactive CD56dimNKG2A+KIR− NK cells. Indeed, CMV
disease is a putative risk factor for the development of PTLD in
liver transplant recipient (41).
Tacrolimus has been reported to increase the viral burden
of EBV in infected humanized mice, leading to more frequent
tumor formation (42). Tacrolimus impairs NK cell proliferation
in a dose-dependent manner and selectively down-regulates the
expression of NKG2D, CD48 and DNAM1 on NK cells (43).
Although the effect of tacrolimus on the expression of NKG2A
has not been investigated in the study by Kim et al., these results
suggest that the immunosuppressive treatment could directly
contribute to the relative reduction of CD56dimNKG2A+KIR−
NK cells in PTLD patients, however, no statistically significant
difference could be identified in our current study. Further
research with a larger study size is needed to investigate the direct
or indirect effects of tacrolimus on the CD56dimNKG2A+KIR−
NK cell subset.
To conclude, we have comprehensively examined the
phenotype and function of distinct NK cell subsets against EBV-
infected B cells in PTLD patients under immunosuppression
during a longitudinal follow-up study. By comparison with
the EBV-associated benign lymphoproliferative disorder
IM, we demonstrate that co-infection of CMV and EBV
diminishes the frequency of CD56dimNKG2A+KIR− NK cells
and may contribute to suboptimal immune control of EBV in
immunosuppressed children with PTLD.
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